Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12531141 | 1.00 | MAPK1 (0.36) | MAPK1CTSCL3MBTL1CHRM2CHRM1 | |
| SCHEMBL19901590 | 0.81 | CYP1A2 (0.42) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL31301933 | 0.81 | CYP1A2 (0.42) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL11457853 | 0.81 | MAPK1 (0.33) | MAPK1CTSCL3MBTL1CHRM2CHRM1 | |
| SCHEMBL4017978 | 0.81 | DPP4 (0.41) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL29308170 | 0.81 | DPP4 (0.41) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL28146362 | 0.81 | DPP4 (0.41) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL695946 | 0.81 | DPP4 (0.41) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| SCHEMBL21673908 | 0.81 | DPP4 (0.41) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL30914110 | 0.80 | DPP4 (0.40) | MAPK1L3MBTL1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | MAPK1 2554/4885CTSC 22/4885L3MBTL1 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.